A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels

2014 ◽  
Vol 24 (3) ◽  
pp. 348-354 ◽  
Author(s):  
Lionne D. F. Venderbos ◽  
Roderick C. N. van den Bergh ◽  
Monique J. Roobol ◽  
Fritz H. Schröder ◽  
Marie-Louise Essink-Bot ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Longitudinal Study ◽  
Active Surveillance ◽  
The Impact

A longitudinal study of patients undergoing active surveillance for low grade prostate cancer diagnosed at Transperineal Template Prostate Mapping

2019 ◽  
Vol 18 (1) ◽  
pp. e615
Author(s):  
M. Kailavasan ◽  
T.J. Walton ◽  
P. Ravindra ◽  
S. Trecarten ◽  
J. Voss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Longitudinal Study ◽  
Active Surveillance ◽  
Low Grade

POD-01.03: The impact of first repeated biopsy in predicting progression in a cohort of prostate cancer patients managed with active surveillance

Urology ◽  
2007 ◽  
Vol 70 (3) ◽  
pp. 1-2
Author(s):  
M.F. Al Otaibi ◽  
N. Fahmy ◽  
P. Ross ◽  
W. Kassouf ◽  
S. Jeyaganth ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Active Surveillance ◽  
The Impact

POD-02.09 Living with Untreated Prostate Cancer: The Impact on Quality of Life of Active Surveillance

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S8
Author(s):  
L. Venderbos ◽  
R. van den Bergh ◽  
M. Roobol ◽  
F. Schröder ◽  
E. Steyerberg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Active Surveillance ◽  
The Impact

Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 5057-5057
Author(s):  
Tom Hope ◽  
Rahul Raj Aggarwal ◽  
Kirsten L Greene ◽  
Bryant Chee ◽  
Dora Tao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Targeted Therapy ◽  
Active Surveillance ◽  
Biochemical Recurrence ◽  
Systemic Treatment ◽  
Major Change ◽  
Substantial Impact ◽  
Psma Pet ◽  
The Impact

5057 Background: PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. The objective was to evaluate the impact of PSMA PET on the management of prostate cancer patients with biochemical recurrence following local therapy. Methods: In our initial Ga-68-PSMA-11 PET protocol (NCT02611882), 150 patients with biochemical recurrence were imaged. 63 patients were imaged using PET/CT (GE Discovery VCT) and 63 patients using PET/MRI (GE Signa 3.0T PET/MRI). 110 patients received Lasix injections. Referring clinicians filled out a pretreatment management form and a management form based on the imaging results. Changes in management were graded as major, minor, no change or unknown based upon the responses. Results: We received both pre and post imaging forms in 126 patients, for an 84% response rate. The average PSA in the population was 5.9 ± 5.4 ng/mL with an average doubling time of 9.7 ± 11.0 months, and 60 patients had a PSA of less than 2.0 at the time of imaging. The average time between prior treatment and imaging (RP and/or radiation) was 5.3 ± 5.4 years, with 46 patients imaged within two years of their most recent treatment. 43 patients had a prior prostatectomy, 41 prior radiation, and 33 patients had both. 103 patients (82%) had disease localized on PSMA imaging. Of the 126 patients, 67 (53%) of the imaging studies resulted in a major change in management. The most common major change was converting from active surveillance to radiation therapy (15 patients, 12%), changing from ADT to radiation therapy (16 patients, 13%), and converting from radiation therapy to either active surveillance (6 patients, 5%) or to ADT alone (3 patients, 2%). 10 patients (8%) had a minor change, 42 patients (33%) had no change, and 7 patients (6%) had an unknown change in management. Conclusions: The results of our surveys demonstrate a substantial impact of PSMA PET on the intended patient management. The majority of changes involved converting a targeted therapy to systemic treatment or systemic treatment to a targeted therapy. Prospective studies are warranted to determine whether directed treatment towards PSMA-avid lesions affects long-term disease outcomes. Clinical trial information: NCT02611882.

Is BMI a risk factor for active surveillance progression in patients with prostate cancer diagnosed by MRI-Trus fusion biopsy?

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 124-124 ◽  
Author(s):  
Kareem Rayn ◽  
Samuel Gold ◽  
Graham R. Hale ◽  
Joey Baiocco ◽  
Jonathan Bloom ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factor ◽  
Active Surveillance ◽  
Progression Free Survival ◽  
Normal Weight ◽  
Fusion Biopsy ◽  
Patient Demographics ◽  
Increased Risk ◽  
Risk Of Progression ◽  
The Impact

124 Background: MRI−TRUS fusion biopsy (FBx) use in the diagnosis of prostate cancer (PCa) results in a more accurate assessment of disease burden and has increasingly been incorporated into urologic practice. In addition, with more men choosing active surveillance (AS) and the reports of increased PCa aggressiveness with obesity, we wanted to study the impact of obesity on the risk of PCa progression in men on AS diagnosed and followed by MRI and MRI−TRUS FBx. Methods: A retrospective review was performed on a prospectively maintained database of all men who underwent MRI−TRUS FBx at our institution from January 2007 to May 2015. Patient demographics, clinical data, imaging, pathology, treatment and outcomes were recorded. Patients who enrolled on AS were stratified by BMI into normal weight (BMI 18.5−24.9), overweight (BMI 25.0−29.9), and obese (BMI ≥ 30.0). Statistical analysis was performed using SPSS software. Results: 204 men were enrolled in AS. Within the AS cohort, 51 (25%) had a normal weight, 101 (49.5%) were overweight, and 52 (25.5%) were obese. Age, BMI, PSA and mean estimated progression free survival time are described for each of these groups in Table 1. The overall rate of progression was 32.8%. Of the patients who progressed, 18 (26.9%) were normal weight, 32 (15.7%) were overweight and 17 (25.4%) were obese. On multivariate analysis, BMI was not a risk factor for AS progression, HR = 1.00 (p = 0.99, 95% CI = 0.95−1.06). Conclusions: There is evidence of increased risk of aggressive PCa specific death in obese patients. However, we demonstrate that in patients diagnosed by FBx, obesity does not confer an additional risk of progression on AS. This may be due to the improved characterization of cancer volume and grade by MRI−TRUS fusion biopsy. Further study is required to determine risk factors for AS progression in patients undergoing FBx. This research was supported by the Intramural Research Program of the National Cancer Institute, NIH, Medical Research Scholars Program.

How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study

2020 ◽  
Vol 29 (2) ◽  
pp. 645-651 ◽  
Author(s):  
Paola Dordoni ◽  
Fabio Badenchini ◽  
Maria Francesca Alvisi ◽  
Julia Menichetti ◽  
Letizia De Luca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Longitudinal Study ◽  
Cancer Patients ◽  
Active Surveillance
Sign in / Sign up

Export Citation Format

Share Document